TORONTO and CAMBRIDGE, MA, May 29,
2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX:
PMN) (OTCQB: ARFXF), a biotechnology company focused on the
discovery and development of antibody therapeutics targeting toxic
oligomers implicated in the development of neurodegenerative
diseases, is participating in the JLABS @ Toronto conference, "Science 1st: Common
Pathways and Mechanisms in Neurodegenerative Diseases" on
May 30, 2019. Executive Chairman
Eugene Williams will speak at the
event, joining speakers from Sunnybrook Research Institute, the
University of Toronto, including the
Tanz Centre for Research in Neurodegenerative Diseases, Johnson and
Johnson Innovations and Conference Sponsor the Ontario Brain
Institute.
The one-day program will highlight new findings in genomics,
imaging and biomarkers for neurodegenerative diseases. Speakers
will describe how these discoveries are redefining these diseases
and invigorating the search for treatments. The event will take
place at JLABS' Toronto location.
Attendees can attend virtually by visiting
https://neurodegenerativediseases.splashthat.com/.
The abnormal misfolding of natural proteins in the brain results
in toxic oligomers that progressively spread (propagate), killing
neurons; the process is a root cause of several neurodegenerative
diseases, including Alzheimer's, Parkinson's and ALS. The lack of
effective therapies for these diseases is due in part to the
traditional approach to developing antibodies, which produced
therapy candidates that are unable to selectively target the toxic
oligomer with adequate precision. Mr. Williams' presentation will
share the results of ProMIS Neurosciences' novel drug discovery and
development platform, which has produced several antibody
candidates that selectively target toxic oligomers of misfolded
proteins while sparing their healthy forms, which are critical for
proper brain and spinal cord function. ProMIS has generated
high-quality potential antibody candidates for Parkinson's,
Alzheimer's and ALS.
"The availability of tools to develop therapies that are highly
selective for only the toxic oligomer has been a missing link in
therapy development for neurodegenerative diseases," said
Eugene Williams, executive chairman
of ProMIS Neurosciences. "The right tools coupled with new
biomarkers will help us advance only the highest quality drug
candidates and in our opinion make this next decade the most
exciting for development of effective root cause therapy to address
the tremendous unmet need of these diseases."
About Johnson & Johnson Innovation – JLABS
Johnson
& Johnson Innovation – JLABS (JLABS) is a global network of
open innovation ecosystems, enabling and empowering innovators
across a broad healthcare spectrum including pharmaceutical,
medical device, consumer and health tech sectors to create and
accelerate the delivery of life-saving, life-enhancing health and
wellness solutions to patients around the world. JLABS achieves
this by providing the optimal environment for emerging companies to
catalyze growth and optimize their research and development by
opening them to vital industry connections, delivering
entrepreneurial programs and providing a capital-efficient,
flexible platform where they can transform the scientific
discoveries of today into the breakthrough healthcare solutions of
tomorrow. At JLABS, we value great ideas and are passionate about
removing obstacles to success to help innovators unleash the
potential of their early scientific discoveries. JLABS is a
no-strings-attached model, which means entrepreneurs are free to
develop their science while holding on to their intellectual
property. JLABS also produces campaigns to seek out the best
science called QuickFire Challenges. For more information,
visit www.jlabs.jnjinnovation.com or
follow @JLABS.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc.
is a development stage biotechnology company focused on discovering
and developing antibody therapeutics selectively targeting toxic
oligomers implicated in the development and progression of
neurodegenerative diseases, in particular Alzheimer's disease (AD),
amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).
The Company's proprietary target discovery platform is based on the
use of two complementary thermodynamic, computational discovery
engines -ProMIS and Collective Coordinates – to predict novel
targets known as Disease Specific Epitopes on the molecular surface
of misfolded proteins. Using this unique precision approach, the
Company is developing novel antibody therapeutics for AD, ALS and
PD. ProMIS is headquartered in Toronto,
Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on
the Toronto Stock Exchange under the symbol PMN, and on the OTCQB
Venture Market under the symbol ARFXF.
Visit us at www.promisneurosciences.com, follow us
on Twitter and LinkedIn, and listen to our podcast, Saving
Minds, at iTunes or Spotify.
The TSX has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. This
information release contains certain forward-looking information.
Such information involves known and unknown risks, uncertainties
and other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-eugene-williams-to-present-at-jlabs-conference-on-innovations-in-neurodegenerative-diseases-300857910.html
SOURCE ProMIS Neurosciences Inc.